Optimal therapy for reduction of lipoprotein(a)

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 1, 2012, Pages 1-3

  Lippi, G ^a   Targher, G ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

apheresis; cardiovascular risk; lipoprotein(a); statins; therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; APOLIPOPROTEIN B100; BEZAFIBRATE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; ROSUVASTATIN; TOCILIZUMAB;

ACUTE CORONARY SYNDROME; APHERESIS; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DRUG ERUPTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TOLERABILITY; DRY SKIN; DYSPEPSIA; FLUSHING; GENETIC VARIABILITY; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERLIPOPROTEINEMIA; HYPERURICEMIA; IN VIVO STUDY; ISCHEMIC HEART DISEASE; LIVER DISEASE; NAUSEA; OUTCOME ASSESSMENT; PRURITUS; REVIEW; RHABDOMYOLYSIS; RHEUMATIC DISEASE; SIDE EFFECT; SIGNAL TRANSDUCTION; STROKE; THROMBOCYTE FUNCTION; TOXIC HEPATITIS;

ATHEROSCLEROSIS; CORONARY DISEASE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; HYPERLIPOPROTEINEMIAS; LIPOPROTEIN(A); STROKE; THROMBOSIS;

EID: 84856359141     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01244.x     Document Type: Review

References (22)

1. Lippi G, Guidi G,. Lipoprotein(a): an emerging cardiovascular risk factor. Critical Reviews in Clinical Laboratory Sciences, 2003; 40: 1-42. (Pubitemid 36250229)
2. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. Journal of the American Medical Association, 2009; 302: 412-423.
3. Kamstrup PR,. Lipoprotein(a) and ischemic heart disease-a causal association? A review. Atherosclerosis, 2010; 211: 15-23.
4. NACB LMPG Committee Members, Myers GL, Christenson RH, Cushman M, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clinical Chemistry, 2009; 55: 378-384.
5. Nordestgaard BG, Chapman MJ, Ray K, et al, European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal, 2010; 31: 2844-2853.
6. Lupattelli G, Roscini AR, Siepi D, Mannarino E,. Case report. Hyperlipoproteinaemia(a): which is the optimal therapy? A case report. Journal of Clinical Pharmacy and Therapeutics, 2010; 35: 613-615.
7. Lippi G, Franchini M, Targher G,. Platelets and lipoprotein(a) in retinal vein occlusion: mutual targets for aspirin therapy. Thrombosis and Haemostasis, 2007; 97: 1059-1060. (Pubitemid 46939226)
8. Lippi G, Tessitore N, Salvagno GL, et al. Influence of haemodialysis on high-sensitivity C-reactive protein, lipoprotein(a), apolipoproteins A and B. Clinical Biochemistry, 2007; 40: 1336-1338. (Pubitemid 47562419)
9. Lippi G, Guidi G,. Biochemical risk factors and patient's outcome: the case of lipoprotein(a). Clinica Chimica Acta, 1999; 280: 59-71. (Pubitemid 29094582)
10. Hartgens F, Rietjens G, Keizer HA, Kuipers H, Wolffenbuttel BH,. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). British Journal of Sports Medicine, 2004; 38: 253-259. (Pubitemid 38748112)
11. Kostner KM, Kostner GM,. Therapy of hyper-Lp(a). Handbook of Experimental Pharmacology, 2005; 170: 519-536.
12. Scanu AM, Bamba R,. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations. American Journal of Cardiology, 2008; 101: 44B-47B.
13. Bruckert E, Labreuche J, Amarenco P,. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis, 2010; 210: 353-361.
14. Kamanna VS, Kashyap ML,. Mechanism of action of niacin. American Journal of Cardiology, 2008; 101: 20B-26B.
15. Capuzzi DM, Morgan JM, Brusco OA, Intenzo CM,. Niacin dosing: relationship to benefits and adverse effects. Current Atherosclerosis Reports, 2002; 2: 64-71.
16. Sanyal S, Kuvin JT, Karas RH,. Niacin and laropiprant. Drugs Today (Barcelona), 2010; 46: 371-378.
17. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, American College of Cardiology, American Heart Association, National Heart, Lung and Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation, 2002; 106: 1024-1028. (Pubitemid 34925341)
18. Cervellin G, Comelli I, Lippi G,. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clinical Chemistry and Laboratory Medicine, 2010; 48: 749-756.
19. Lippi G, Braga V, Adami S, Guidi G,. Modification of serum apolipoprotein A-I, apolipoprotein B and lipoprotein(a) levels after bisphosphonates-induced acute phase response. Clinica Chimica Acta, 1998; 271: 79-87. (Pubitemid 28123504)
20. Rodríguez M, Ringstad L, Schäfer P, Just S, Hofer HW, Malmsten M, Siegel G,. Reduction of atherosclerotic nanoplaque formation and size by Ginkgo biloba (EGb 761) in cardiovascular high-risk patients. Atherosclerosis, 2007; 192: 438-444. (Pubitemid 46726344)
21. Lippi G, Targher G, Guidi GC,. Ginkgo biloba, inflammation and lipoprotein(a). Atherosclerosis, 2007; 195: 417-418. (Pubitemid 350087975)
22. Schultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, Krone W, Laudes M,. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid disease. PLoS ONE, 2010; 5: e14328.